BIOLINERX     Print Page  Close Window

2014 Press releases
E-mail Alerts Receive e-mail alerts | RSS Rss feeds
Keyword search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
12/23/14BioLineRx Out-Licenses Novel Skin Lesion Treatment to Omega PharmaPrinter Friendly Version
12/16/14BioLineRx and Major Global Pharmaceutical Company Form Strategic Collaboration for Screening and Development of Novel Drug CandidatesPrinter Friendly Version
12/12/14BioLineRx Presents Multi-Year Clinical Development Plan for its BL-8040 Hematological Cancer Therapeutic PlatformPrinter Friendly Version
12/08/14BioLineRx Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at ASH ConferencePrinter Friendly Version
11/10/14BioLineRx Reports Third Quarter 2014 Financial ResultsPrinter Friendly Version
11/05/14BioLineRx Announces Successful Final Results of Phase 1/2 Study for Novel Celiac TreatmentPrinter Friendly Version
11/03/14BioLineRx to Report Third Quarter 2014 Results on November 10, 2014Printer Friendly Version
11/03/14BioLineRx Files Protocol Amendment to Phase 2 Study for AML Treatment based on Encouraging Efficacy and Strong Safety ProfilePrinter Friendly Version
10/31/14BioLineRx Reports Publication in Peer Review Journal of Results from Previous Phase 1/2 Trial for BCM (BL-1040), a Novel Medical Device for Prevention of Cardiac Remodeling Following Acute Myocardial InfarctionPrinter Friendly Version
09/17/14BioLineRx Presents Positive Preclinical Results in Treatment for AML Patients with FLT3 MutationsPrinter Friendly Version
09/03/14BioLineRx Doses First Patient for BL-8040’s Second Indication as Novel Stem Cell Mobilization TreatmentPrinter Friendly Version
09/02/14BioLineRx to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New YorkPrinter Friendly Version
08/21/14BioLineRx Receives Notice of Allowance for US Patent on BL-7010 Covering Use of Novel Polymer in Prevention of Gluten ToxicityPrinter Friendly Version
08/06/14BioLineRx Reports Second Quarter 2014 Financial ResultsPrinter Friendly Version
07/30/14BioLineRx to Report Second Quarter 2014 Results on August 6, 2014Printer Friendly Version
07/16/14BioLineRx Announces Results from Phase 1/2 Study for Celiac TreatmentPrinter Friendly Version
06/23/14BioLineRx In-Licenses Novel Compound for Treatment of Neuropathic PainPrinter Friendly Version
06/16/14BioLineRx Receives Approval to Commence Phase 1 Trial for Novel Stem Cell Mobilization TreatmentPrinter Friendly Version
06/11/14BioLineRx Receives Notice of Allowance for US Patent Covering Novel Treatment for Celiac DiseasePrinter Friendly Version
05/30/14BioLineRx Enters into Share Purchase Agreement with Lincoln Park CapitalPrinter Friendly Version
05/20/14BioLineRx Reports First Quarter 2014 Financial ResultsPrinter Friendly Version
05/15/14BioLineRx to Report First Quarter 2014 Results on May 20, 2014Printer Friendly Version
04/10/14BioLineRx Announces Investigator-Initiated Study for Novel Chronic Myeloid Leukemia TreatmentPrinter Friendly Version
03/17/14BioLineRx Reports Year End 2013 Financial ResultsPrinter Friendly Version
03/14/14BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 in ImmunotherapyPrinter Friendly Version
03/11/14BioLineRx to Report Fourth Quarter and Year End 2013 Results on March 17, 2014Printer Friendly Version
03/10/14BioLineRx Completes Dose Escalation Stage of Phase 1/2 Study for Novel Celiac TreatmentPrinter Friendly Version
03/07/14BioLineRx Closes $24.1 Million Underwritten Public Offering of its American Depositary SharesPrinter Friendly Version
03/05/14BioLineRx to Present at the Annual ROTH Growth Stock Conference in CaliforniaPrinter Friendly Version
03/04/14BioLineRx Prices $21.0 Million Underwritten Public Offering of its American Depositary SharesPrinter Friendly Version
03/03/14BioLineRx Announces Underwritten Public Offering of its American Depositary SharesPrinter Friendly Version
02/24/14BioLineRx Appoints Dr. Sandra Panem to Board of DirectorsPrinter Friendly Version
02/12/14BioLineRx Announces Positive Preclinical Results for Novel Treatment for Chronic Myeloid LeukemiaPrinter Friendly Version
02/03/14BioLineRx to Present at the 2014 BIO CEO & Investor Conference in New York on February 10Printer Friendly Version
01/23/14BioLineRx Receives Orphan Drug Designation for Novel Stem Cell Mobilization TreatmentPrinter Friendly Version
01/21/14BioLineRx Receives Approval to Commence Pivotal Trial for Novel Skin Lesion TreatmentPrinter Friendly Version
01/13/14BioLineRx Announces Regulatory Submission for Novel Stem Cell Mobilization TreatmentPrinter Friendly Version
01/08/14BioLineRx and JHL Biotech to Collaborate on Type 1 Diabetes Antibody TreatmentPrinter Friendly Version
01/07/14BioLineRx to Present at Biotech Showcase Conference in San FranciscoPrinter Friendly Version